DOI: https://doi.org/10.22263/2312-4156.2025.5.17
K.S. Lutskovich, A.N. Meleshko, D.V. Lutskovich
CAR-T cell therapy as a promising treatment for systemic lupus erythematosus (literature review)
Republican Scientific and Practical Cener for Pediatric Oncology, Hematology and Immunology, Borovlyany village, Minsk, Republic of Belarus
Vestnik VGMU. 2025;24(5):17-29.
Abstract.
Systemic lupus erythematosus (SLE) is a complex autoimmune disorder characterized by the production of autoreactive B and T cells and cytokines, leading to chronic inflammation affecting multiple organs. The typical manifestation is the skin and joint clinical signs of SLE, also patients may have severe lupus nephritis, autoimmune cytopenia, and damage to the heart, lungs, or central nervous system, which can lead to life-threatening complications and death. At present the overall ten-year survival rate of patients with SLE ranges from 83% to 93%, while the 15-year survival rate drops to 76–80%. CAR-T therapy used to treat B-cell malignancies has become an innovative approach to treat severe autoimmune diseases, including systemic lupus erythematosus (SLE). Conventional treatment methods for SLE often cause significant side effects and limited efficacy, necessitating the search for novel therapeutic strategies. The immunological justification for treating B-cell autoimmune diseases with targeting antibodies is well established and has been demonstrating its efficacy for several years. However, this approach is often ineffective in SLE. Recent data from the use of CAR-T therapy have shown promising results in terms of long-term remission. This article provides an overview of CAR-T therapies used for SLE including the list of clinical trials and a description of targets suitable for CAR-T cell targeting. We also summarize clinical data on the safety and efficacy of anti-CD19 and anti-B cell maturation antigen (BCMA) CAR-T cells in targeting B-cells in SLE.
Keywords: CAR-T therapy, systemic lupus erythematosus, CD19, BCMA, autoimmune diseases.
References
1. Dao LTM, Vu TT, Nguyen QT, Hoang VT, Nguyen TL. Current cell therapies for systemic lupus erythematosus. Stem Cells Translational Medicine. 2024 Sep;13(9):859-872. doi: http://dx.doi.org/10.1093/stcltm/szae044
2. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2019 Jun;78(6):736-745. doi: http://dx.doi.org/10.1136/annrheumdis-2019-215089
3. Abdalhadi HM, Chatham WW, Alduraibi FK. CAR-T-Cell Therapy for Systemic Lupus Erythematosus: A Comprehensive Overview. International Journal of Molecular Sciences. 2024 Sep;25(19):10511. doi: http://dx.doi.org/10.3390/ijms251910511
4. Davidson A. What is damaging the kidney in lupus nephritis? Nature Reviews Rheumatology. 2016 Mar;12(3):143-53. doi: http://dx.doi.org/10.1038/nrrheum.2015.159
5. Jorge A, Wallace ZS, Zhang Y, Lu N, CostenbaderKH, Choi HK. All-Cause and Cause-Specific Mortality Trends of End-Stage Renal Disease Due to Lupus Nephritis From 1995 to 2014. Arthritis and Rheumatology. 2019 Mar;71(3):403-410. doi: http://dx.doi.org/10.1002/art.40729
6. Zen M, Salmaso L, C. Amidei B, Fedeli U, Bellio S, Iaccarino L, et al. Mortality and causes of death in systemic lupus erythematosus over the last decade: Data from a large population-based study. European Journal of Internal Medicine. 2023 Jun:112:45-51. doi: http://dx.doi.org/10.1016/j.ejim.2023.02.004
7. Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2020 Apr;23(4):465-471. doi: http://dx.doi.org/10.1111/1756-185X.13817
8. Canny SP, Jackson SW. B Cells in Systemic Lupus Erythematosus: From Disease Mechanisms to Targeted Therapies. Rheumatic Diseases Clinics of North America. 2021 Aug;47(3):395-413. doi: http://dx.doi.org/10.1016/j.rdc.2021.04.006
9. Marmont AM, van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus. 1997;6(6):545-8. doi: http://dx.doi.org/10.1177/096120339700600613
10. Zhou J, Lei B, Shi F, Luo X, Wu K, Xu Y, et al. CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives. Frontiers in Immunology. 2024 Dec 19:15:1476859. doi: http://dx.doi.org/10.3389/fimmu.2024.1476859
11. Alexander T, Greco R. Hematopoietic stem cell transplantation and cellular therapies for autoimmune diseases: overview and future considerations from the Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation. 2022 Jul;57(7):1055-1062. doi: http://dx.doi.org/10.1038/s41409-022-01702-w
12. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T Cell Immunotherapy for Human Cancer. Science. 2018 Mar;359(6382):1361-1365. doi: http://dx.doi.org/10.1126/science.aar6711
13. Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Thuy Pham AH, et al. CAR-T design: Elements and their synergistic function. EBioMedicine. 2020 Aug:58:102931. doi: http://dx.doi.org/10.1016/j.ebiom.2020.102931
14. Alnefaie A, Albogami S, Asiri Y, Ahmad T, Alotaibi SS, Al-Sanea MM, et al. Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. Frontiers in Bioengineering and Biotechnology. 2022 Jun:10:797440. doi: http://dx.doi.org/10.3389/fbioe.2022.797440
15. Arbabi-Ghahroudi M. Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences. 2022 Apr;23(9):5009. doi: http://dx.doi.org/10.3390/ijms23095009
16. Gabriele F, Palerma M, Ippoliti R, Angelucci F, Pitari G, Ardini M. Recent Advances on Affibody- and DARPin-Conjugated Nanomaterials in Cancer Therapy. International Journal of Molecular Sciences. 2023;24(10):8680. doi: http://dx.doi.org/10.3390/ijms24108680
17. Turtle CJ, Riddell SR, Maloney DG. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies. Clinical Pharmacology and Therapeutics. 2016 Sep;100(3):252-8. doi: http://dx.doi.org/10.1002/cpt.392
18. Qin L, Lai Y, Zhao R, Wei X, Weng J, Lai P, et al. Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells. Journal of Hematology and Oncology. 2017 Mar;10(1):68. doi: http://dx.doi.org/10.1186/s13045-017-0437-8
19. Fujiwara K, Tsunei A, Kusabuka H, Ogaki E, Tachibana M, Okada N. Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold. Cells. 2020 May;9(5):1182. doi: http://dx.doi.org/10.3390/cells9051182
20. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, et al. The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity. Cancer Immunology Research. 2015 Feb;3(2):125-135. doi: http://dx.doi.org/10.1158/2326-6066.CIR-14-0127
21. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells: Modification of the IgG1 Fc spacer domain in the extracellular moiety of chimeric antigen receptors avoids off-target activation and unintended initiation of an innate immune response. Gene Therapy. 2010 Oct;17(10):1206-1213. doi: http://dx.doi.org/10.1038/gt.2010.91
22. Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, et al. The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in Immunology. 2021 Mar:12:639818. doi: http://dx.doi.org/10.3389/fimmu.2021.639818
23. Bezbradica JS, Medzhitov R. Role of ITAM signaling module in signal integration. Current Opinion in Immunology. 2012 Feb;24(1):58-66. doi: http://dx.doi.org/10.1016/j.coi.2011.12.010
24. Dejenie TA, Tiruneh G/Medhin M, Terefe GD, Admasu FT, Tesega WW, Abebe EC. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Human Vaccines and Immunotherapeutics. 2022 Nov 30;18(6):2114254. doi: http://dx.doi.org/10.1080/21645515.2022.2114254
25. Lutskovich D, Meleshko A, Katsin M. State of the art and perspectives of chimeric antigen receptor T cells cell therapy for neuroblastoma. Cytotherapy. 2024 Oct;26(10):1122-1131. doi: http://dx.doi.org/10.1016/j.jcyt.2024.05.011
26. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. The Journal of Clinical Investigation. 2011 May;121(5):1822-1826. doi: http://dx.doi.org/10.1172/JCI46110
27. Gandhi M, Jones K. Optimizing tumor-targeting chimeric antigen receptor T cells in B-cell lymphoma patients. Immunotherapy. 2011 Dec;3(12):1441-1443. doi: http://dx.doi.org/10.2217/imt.11.135
28. Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, et al. An immunoproteomic approach to characterize the CAR interactome and signalosome. Science Signaling. 2019 Feb;12(568):eaap9777. doi: http://dx.doi.org/10.1126/scisignal.aap9777
29. Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, et al. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. Cancer Immunology Research. 2017 Jul;5(7):571-581. doi: http://dx.doi.org/10.1158/2326-6066.CIR-16-0376
30. Chmielewski M, Abken H. TRUCKs: The fourth generation of CARs. Expert Opinion on Biological Therapy. 2015;15(8):1145-1154. doi: http://dx.doi.org/10.1517/14712598.2015.1046430
31. Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, et al. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nature Medicine. 2018;24(3):352-359.
32. Nair S, Wang JB, Tsao ST, Liu Y, Zhu W, Slayton WB, et al. Functional Improvement of Chimeric Antigen Receptor Through Intrinsic Interleukin-15Rα Signaling. Current Gene Therapy. 2019;19(1):40-53. doi: http://dx.doi.org/10.2174/1566523218666181116093857
33. Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. Journal of Hematology and Oncology. 2018 Nov;11(1):132. doi: http://dx.doi.org/10.1186/s13045-018-0677-2
34. Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011 Nov;118(18):4817-4828. doi: http://dx.doi.org/10.1182/blood-2011-04-348540
35. Vairy S, Garcia JL, Teira P, Bittencourt H. CTL019 (Tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia. Drug Design Development and Therapy. 2018 Nov:12:3885-3898. doi: http://dx.doi.org/10.2147/DDDT.S138765
36. Martino M, Alati C, Canale FA, Musuraca G, Martinelli G, Cerchione C. A Review of Clinical Outcomes of CAR T-Cell Therapies for B-Acute Lymphoblastic Leukemia. International Journal of Molecular Sciences. 2021 Feb;22(4):2150. doi: http://dx.doi.org/10.3390/ijms22042150
37. Hopfinger G, Jäger U, Worel N. CAR-T Cell Therapy in Diffuse Large B Cell Lymphoma: Hype and Hope. HemaSphere. 2019 Mar;3(2):e185. doi: http://dx.doi.org/10.1097/HS9.0000000000000185
38. Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020 Sep;396(10254):839-852. doi: http://dx.doi.org/10.1016/S0140-6736(20)31366-0
39. Boettcher M, Joechner A, Li Z, Yang SF, Schlegel P. Development of CAR T Cell Therapy in Children-A Comprehensive Overview. Journal of Clinical Medicine. 2022 Apr2;11(8):2158. doi: http://dx.doi.org/10.3390/jcm11082158
40. Munshi NC, Anderson LD, Shah N, Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. The New England Journal of Medicine. 2021 Feb;384(8):705-716. doi: http://dx.doi.org/10.1056/NEJMoa2024850
41. Abebe CE, Shiferaw MY, Admasu FT, Dejenie TA. Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma. Frontiers in Immunology. 2022 Sep:13:991092. doi: http://dx.doi.org/10.3389/fimmu.2022.991092
42. Kambayana G, Rini SS. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment. Current Rheumatology Reviews. 2023 Jun;19(3):260-269. doi: http://dx.doi.org/10.2174/1573397119666230214103044
43. Mougiakakos D, Kronke G, Volkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. The New England Journal of Medicine. 2021 Aug;385(6):567-569. doi: http://dx.doi.org/10.1056/NEJMc2107725
44. Katarzyna PB, Wiktor S, Ewa D, Piotr L. Current treatment of systemic lupus erythematosus: a clinician's perspective. Rheumatology International. 2023 Aug;43(8):1395-1407. doi: http://dx.doi.org/10.1007/s00296-023-05306-5
45. Liao J, Chang C, Wu H, Lu Q. Cell-based therapies for systemic lupus erythematosus. Autoimmunity Reviews. 2015 Jan;14(1):43-48. doi: http://dx.doi.org/10.1016/j.autrev.2014.10.001
46. Jin X, Xu Q, Pu C, Zhu K, Lu C, Jiang Y, et al. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cellular and Molecular Immunology. 2021 Aug;18(8):1896-1903. doi: http://dx.doi.org/10.1038/s41423-020-0472-1
47. Taubmann J, Müller F, Mutlu MY, Völkl S, Aigner M, Bozec A, et al. CD19 chimeric antigen receptor T cell treatment: unraveling the role of B cells in systemic lupus erythematosus. Arthritis and Rheumatology. 2024 Apr;76(4):497-504. doi: http://dx.doi.org/10.1002/art.42784
48. Mei HE, Schmidt S, Dörner T. Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Research and Therapy. 2012;14 Suppl 5:S1. doi: http://dx.doi.org/10.1186/ar3909
49. Labanieh L, Mackall CL. CAR immune cells: design principles, resistance and the next generation. Nature. 2023 Feb;614(7949):635-648. doi: http://dx.doi.org/10.1038/s41586-023-05707-3
50. Cappell KM, Kochenderfer JN. Long-term outcomes following CAR T cell therapy: what we know so far. Nature reviews. Clinical Oncology. 2023 Jun;20(6):359-371. doi: http://dx.doi.org/10.1038/s41571-023-00754-1
51. Tanaka Y. State-of-the-art treatment of systemic lupus erythematosus. International Journal of Rheumatic Diseases. 2020 Apr;23(4):465-471. doi: http://dx.doi.org/10.1111/1756-185X.13817
52. Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Science Translational Medicine. 2019 Sep;11(511):eaaw9414. doi: http://dx.doi.org/10.1126/scitranslmed.aaw9414
53. Basta F, Fasola F, Triantafyllias K, Schwarting A. Systemic Lupus Erythematosus (SLE) Therapy: The Old and the New. Rheumatology and Therapy. 2020 Sep;7(3):433-446. doi: http://dx.doi.org/10.1007/s40744-020-00212-9
54. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, Yang S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clinical Cancer Research. 2013 Apr;19(8):2048-2060. doi: http://dx.doi.org/10.1158/1078-0432.CCR-12-2422
55. Salazar-Camarena DC, Palafox-Sánchez CA, Cruz A, Marín-Rosales M, Muñoz-Valle JF. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. Scientific Reports. 2020 Apr;10(1):6236. doi: http://dx.doi.org/10.1038/s41598-020-63390-0
56. Garfall AL, Cohen AD, Susaniba-Adaniya S, Hwang WT, Vogl DT, Waxman AJ, et al. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discovery. 2023 Mar;4(2):118-133. doi: http://dx.doi.org/10.1158/2643-3230.BCD-22-0074
57. Zhang W, Feng J, Cinquina A, Wang Q, Xu H, Zhang Q, et al. Treatment of systemic lupus erythematosus using BCMA-CD19 compound CAR. Stem Cell Reviews and Reports. 2021 Dec;17(6):2120-2123. doi: http://dx.doi.org/10.1007/s12015-021-10251-6
Submitted 01.08.2025
Accepted 21.10.2025
Information about authors:
Ekaterina S. Lutskovich – Junior Researcher of the Laboratory of Genetic Biotechnologies, Republican Scientific and Practical Cener for Pediatric Oncology, Hematology and Immunology, https://orcid.org/0009-0000-1820-6806, e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра.;
A.N. Meleshko – Candidate of Biological Sciences, Leading Researcher of the Laboratory of Genetic Biotechnologies, Republican Scientific and Practical Cener for Pediatric Oncology, Hematology and Immunology, https://orcid.org/0000-0001-6964-3635
D.V. Lutskovich – Researcher of the Laboratory of Genetic Biotechnologies, Republican Scientific and Practical Cener for Pediatric Oncology, Hematology and Immunology, https://orcid.org/0000-0002-3998-8023
